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ABSTRACT
In trypanosomes a 39 nucleotide exon, the spliced
leader (SL) is donated to all mRNAs from a small
RNA, the SL RNA, by trans-splicing. Since the dis-
covery of trans-splicing in trypanosomes two
decades ago, numerous attempts failed to reconsti-
tute the reaction in vitro. In this study, a crude
whole-cell extract utilizing the endogenous SL
RNA and synthetic tubulin pre-mRNA were used to
reconstitute the trans-splicing reaction. An RNase
protection assay was used to detect the trans-
spliced product. The reaction was optimized and
shown to depend on ATP and intact U2 and U6
snRNPs. Mutations introduced at the polypyrimidine
tract and the AG splice site reduced the reaction
efficiency. To simplify the assay, RT–PCR and quan-
titative real-time PCR assays were established. The
system was used to examine the structural require-
ments for SL RNA as a substrate in the reaction.
Interestingly, synthetic SL RNA assembled poorly
to its cognate particle and was not utilized in the
reaction. However, SL RNA synthesized in cells
lacking Sm proteins, which is defective in cap-4
modification, was active in the reaction. This study
is the first step towards further elucidating the
mechanism of trans-splicing, an essential reaction
which determines the trypanosome transcriptome.
INTRODUCTION
mRNA maturation in trypanosomes diﬀers from the
process in most eukaryotes mainly because in
trypanosomes, protein coding genes are transcribed into
polycistronic RNAs. The polycistronic RNAs are dis-
sected to individual mature mRNAs by the concerted
action of trans-splicing and polyadenylation. Thus,
trans-splicing functions to release mature capped
mRNAs from the polycistronic RNA. In trans-splicing,
a small RNA, the spliced leader RNA (SL RNA) harbor-
ing a special cap-4 and composed of a conserved exon (SL)
and a more divergent intron, donates its exon to all
mRNAs (1,2). Trans-splicing, like cis-splicing, proceeds
through a two-step transesteriﬁcation reaction, though a
Y structure is formed instead of a lariat intermediate.
Although ﬁrst discovered in trypanosomes, trans-splicing
was later found in nematodes, trematodes and even
chordates (3), and more recently also in dinoﬂagellates
(4). Cis-splicing also occurs in trypanosomes, but so
far only three substrates were shown to undergo this
process (5).
SL RNA is transcribed from a RNA polymerase II
promoter (6,7). SL RNA undergoes modiﬁcation to
form the unique hypermethylated cap-4 (8). However,
eliminating an individual cap modiﬁcation does not inter-
fere with the ability of the SL RNA to undergo trans-
splicing (9). The SL RNA binds core Sm proteins, which
are assisted by SMN and Gemin2 (10). SL RNA
undergoes pseudouridylation by SLA1, which serves as a
chaperone during SL RNA biogenesis. SL RNA transcrip-
tion, pseudouridylation and assembly with core
Sm proteins take place in a special nuclear location that
we termed the SL RNP factory (11,12). The majority of
SL RNA in the steady state is concentrated in this
sub-domain (12,13). It is not currently known how the
SL RNP is recruited to the trans-spliceosome.
Recently, much progress was made in identifying a
variety of trypanosome splicing factors, and their func-
tions were elucidated by down-regulation via RNAi
(10,12,14–19). Splicing defects such as an increase in the
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ture intermediate were observed following the depletion of
each splicing factor (18,19). Using this approach, the
factors U2AF35, U2AF65 and SF1, which function to
identify and specify the correct 30 AG splice sites, were
recently identiﬁed. The Trypanosoma brucei U2AF65 is
larger than its mammalian counterpart, and surprisingly,
unlike the protein’s interactions in metazoa, it interacts
with SF1 but not with U2AF35 (20). An  45S
spliceosomal complex was identiﬁed, suggesting the exis-
tence of a single-spliceosome complex that can potentially
conduct both cis- and trans-splicing (19).
In vitro splicing reactions were established in mamma-
lian and yeast extracts >25 years ago (21–23). A very eﬃ-
cient in vitro trans-splicing reaction was also established in
nematodes using Ascaris lumbricoides whole-cell extracts
derived from developing embryos. The reaction is very
eﬃcient and is based on a synthetic pre-mRNA acceptor
and SL RNA derived from the extract, or synthetic
radiolabeled SL RNA (24,25). The in vitro cis-splicing
systems in both mammals and yeast required diﬀerent
manipulations in order to optimize the reactions.
Although whole-cell extracts were used in the mammalian
system, nuclear extracts were later found to be more eﬃ-
cient (21). The in vitro reaction is more eﬃcient using
‘tailored’ RNA molecules harboring introns which are
derived from transcripts that are spliced in vivo with
high eﬃciency. For instance, the ﬁrst splicing substrate
was constructed using exons and an intron from the
adenovirus transcription unit (21,23) and a better
substrate was subsequently obtained by shortening the
exon size (26). It was demonstrated in the mammalian
system that the pre-mRNA does not require either a cap
at its 50-end or a poly-(A)
+ tail for its splicing, but splicing
is enhanced by the addition of a cap, probably due to
stabilization of the pre-mRNA (27). In yeast, a cell-free
splicing system was ﬁrst established using a sensitive S1
nuclease assay monitoring the production of the spliced
product, and later, radiolabeled pre-mRNA was used and
the spliced product and intermediates were readily
detected (22). Despite overcoming many hurdles in estab-
lishing in vitro splicing systems in mammals and yeast as
mentioned above, the insights obtained did not prove to
be useful for creating such an in vitro trans-splicing
reaction in trypanosomes.
In this study, we established an in vitro trans-splicing
system using substrates whose trans-splicing was ﬁrst
veriﬁed in vivo in transgenic parasites expressing these con-
structs. The model substrate contains the splicing signals
of the b-tubulin gene fused to luciferase and the upstream
polyadenylation signal of the a-tubulin gene. Three sensi-
tive assays were established to monitor the production of
the trans-spliced product, RNase protection, RT–PCR
and a quantitative real-time PCR (qRT–PCR) assay.
Trans-splicing requires ATP, is sensitive to heat-
inactivation, and is dependent on U2 and U6 snRNAs.
The reaction is inhibited when the AG splice site or the
polypyrimidine tract are mutated. Mutant SL RNA,
lacking the cap-4 +4 modiﬁcation, can be utilized in
trans-splicing, and synthetic cap-4 does not inhibit the
reaction. Optimization of the reaction conditions indicates
that SL RNA is the limiting component in the extract, but
only endogenous and not m
7G capped synthetic SL RNA
is active in the reaction. This system can be further used to
investigate in depth the mechanism and ﬁdelity of 30 splice
site selection.
MATERIALS AND METHODS
Cell growth, transfection and cloning
All experiments were performed with the procyclic form of
T. brucei strain 29–13. Cell culture and preparation of
transgenic parasites was as previously described (14).
Plasmids
pNS21 was a kind gift from George Cross (Rockefeller
University, USA). This plasmid contains the T. brucei
procyclin promoter, followed by a linker containing a
BglII restriction site, the procyclin (EP) 30 splice site and
synthetic 50UTR, fused to the luciferase ORF that
contains an XbaI restriction site 47-nt downstream from
the ATG start codon. This vector contains the phleomycin
resistance gene (28). To create plasmids carrying the
splicing signals of b-tubulin or EP, the corresponding
sequences were ampliﬁed from the genome and were
cloned between the restriction sites BglII and XbaI (28).
To generate the vector pNS21-TIR carrying the b-tubulin
intergenic region, a PCR product was generated using
forward primer (233-Tub-luc f1) and reverse primer
(234-Tub-Luc.r1) to create the correct fusion. Similarly,
the pNS21-PIR was generated by amplifying the EP-2-3
(Tb927.6.520; positions 226182-227114 on chromosome 6)
with forward primer (246-EP-luc f1) and reverse primer
(247-EP-luc r1) to create a fusion with the luciferase gene.
The plasmids were linearized with NotI for integration
into the rRNA locus. RNA from transgenic parasites
was used to prepare cDNA using the Reverse-iT
(Thermo Scientiﬁc) kit with random primers. The cDNA
was ampliﬁed using SL forward primer (220, SL RNA
sense) and the luciferase reverse primer (575, T7 Luc
52-67 as). These cDNA clones were used to prepare the
probes for the RNase protection assay described below.
The oligonucleotide list is given in Supplementary Data 1.
Mutants of pNS21-TIR
The mutations that changed the polypyrimidine tract
(PPTm), AG to AA, and the pNS21-TIRsub were
generated by site directed mutagenesis using the Mega
primer method. The mutants were generated using a
forward primer and a reverse primer carrying the
mutation, and a second pair composed of a sense primer
carrying the mutation and a reverse primer containing the
XbaI site (234). The two fragments carrying the mutation
were ampliﬁed using the primer pair 233 and 234. The
mutated fragments were cloned between the XbaI and
BglII site of pNS21, and the plasmids were sequenced
and used to prepare transgenic cell lines. cDNA from
these cell lines were cloned and sequenced. The pairs of
oligonucleotides used to generate the mutations are listed
in Supplementary Data 1.
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Extracts were prepared essentially as described (29), with
minor changes. First, 2l of T. brucei 29-13 were grown in a
5l conical ﬂask under constant stirring to a density of
1 10
7 cells/ml. Cells were harvested at 4 C, yielding a
packed cell volume of around 1.5ml. Cell pellets were
washed twice in 10ml of ice-cold wash solution [20mM
Tris–HCl (pH 7.4), 100mM NaCl, 3mM MgCl2,1 m M
EDTA] and once in 10ml of ice-cold transcription buﬀer
[150mM sucrose, 20mM potassium L-glutamate, 3mM
MgCl2, 20mM HEPES-KOH (pH 7.7), 2mM
dithiothreitol, and leupeptin (10mg/ml)]. Finally, pellets
were suspended in 3ml of transcription buﬀer and
incubated for 20min on ice. Cells were broken in a 7-ml
Dounce homogenizer with a type B pestle by applying
rapid strokes continuously for  5min, until >75% of
the cells were broken. The suspension was divided into
1ml aliquots, frozen in liquid nitrogen and stored at
 70 C. For a whole-cell extract preparation, an aliquot
was thawed, 900ml was mixed with 100ml of transcription
buﬀer containing 1.5M KCl, and incubated for 20min on
ice with frequent mixing. Subsequently, the extract was
centrifuged at 21000g for 10min at 4 C. The supernatant
( 600ml) was transferred to a new microtube, diluted with
0.5 volumes of transcription buﬀer, and centrifuged again
for 2min. The supernatant was loaded on an Amicon
Ultra-4, 5kDa MWCO (Millipore) to concentrate the
extract. When the volume reached  500ml, a second salt
dilution to 40mM KCl was performed by adding 750ml
transcription buﬀer, and the sample was further
concentrated until a ﬁnal volume of 150–200ml was
reached. The ﬁnal cell extract was divided into  50ml
aliquots, frozen, and stored at  70 C. Protein concentra-
tion of extracts varied between 40 and 50mg/ml.
In vitro trans-splicing
The reaction buﬀer was essentially as described (30) with
minor changes. Each 20ml reaction mixture contained 8ml
cell extract (300–500mg protein) in 20mM potassium
L-glutamate, 20mM KCl, 3mM MgCl2, 20mM HEPES–
KOH, pH 7.7, 20mM creatine phosphate, 0.48mg/ml
creatine kinase, 2.5% polyethylene glycol, 0.2mM
EDTA, 0.5mM EGTA, 4mM dithiothreitol, 10mg/ml
leupeptin, 10mg/ml aprotinin and 25mg/ml pre-mRNA
substrate (0.5mg). ATP (0.5mM) was added after 15min
incubation on ice, and then the reaction was continued for
1h at 28 C. When co-transcriptional trans-splicing was
examined, 0.5mM NTP mix was added to the reaction
and 40mg/ml of pNS21-TIR plasmid DNA was used.
Total RNA was prepared and analyzed by RNase protec-
tion assay as previously described (14), except that RNA
was extracted from the in vitro reaction using TriReagent
(Sigma). RNase protection assay products were separated
on 6% polyacrylamide/7M urea gels and visualized by
autoradiography.
RNA preparation for the in vitro reaction
Total RNA from the transgenic parasites was prepared
using TriReagent (Sigma). To generate pre-mRNA for
the trans-splicing reaction, PCR products were prepared
using a sense primer containing the T7 promoter. The T7
in vitro transcribed pre-TIR and its derivate mutations
were prepared with sense primer 259, and antisense
primer 218 situated 86nt downstream of the luciferase
ATG. Synthetic SL RNA was prepared using primers
775 and 777, and plasmid coding for T. brucei SL RNA
(14). RNA was synthesized using the MegaScript T7 Kit
(Ambion) according to the manufacturer’s instructions.
[a-
32P]-UTP-labeled antisense probes for RNase protec-
tion assay were prepared by using T7 RNA polymerase
(Promega).
Isolation of SL RNA transcribed in the cells
The synthesis of [a-
32P]-UTP-labeled SL RNA in perme-
able cells was essentially as described (31). For isolation of
native SL RNA, total RNA was prepared from 250ml
T. brucei parental strain ( 1mg) and separated on a
10% acrylamide denaturing gel. SL RNA co-migrates on
such gels together with the 140nt srRNA-3. RNA was
visualized by UV lamp on a TLC plate. The  140nt
RNA species was excised from the gel. SL RNA concen-
tration was determined by primer extension using synthet-
ically transcribed SL RNA as a standard (0.08 to 8ng).
Based on the primer extension calibration curve, the con-
centration of gel-extracted SL RNA was estimated to be
0.35ng/ml.
RNase H digestion of U snRNAs in the splicing extracts
RNase H digestion was performed as follows: In vitro
splicing extract (300–500mg) was incubated with
200 pmol of primer, 0.4mM ATP and 1U RNase H
(New England Biolabs, USA) in a total reaction volume
of 20ml, for 90min on ice. The reaction was then split.
Half of the treated extract was used for an in vitro
reaction and the other half was subjected to primer exten-
sion. The primers used for RNase H cleavage are listed in
Supplementary Data 1.
RT–PCR as a trans-splicing assay
In vitro trans-splicing reaction was performed as described
above and RNA was extracted by Proteinase K treatment,
followed by phenol:chloroform extraction and ethanol
precipitation. The cDNA was prepared from one
standard 20ml splicing reaction using random primer
and the RevertAid
TM First Strand cDNA synthesis kit
(Fermentas) following the manufacturer’s instructions.
PCR was performed on 0.1ml of cDNA, 1mM primers
and ReadyMix
TM Taq PCR Reaction Mix with MgCl2
(Sigma). The PCR conditions were as follows: 95  for
2min followed by 30 cycles of 95  for 30s, 60  for 30s
and 72  for 10s (for pNS21-TIRsub mRNA ampliﬁcation)
or for 30s (for pNS21-TIRsub pre-mRNA and Tubulin
ampliﬁcation).
Quantitative real-time PCR
Real-time PCR was performed in a two-step reaction.
First, cDNA was prepared from either 10mg of total
RNA or a standard in vitro trans-splicing reaction using
PAGE 3 OF 17 Nucleic Acids Research, 2010,Vol.38, No. 10 e114random primer and the RevertAid
TM First Strand cDNA
synthesis kit (Fermentas) following the manufacturer’s
instructions. Next, real-time PCR was performed using
1ml of cDNA (diluted 1:100), 1mM primers and
Absolute Blue QPCR SYBR Green ROX mix (Thermo
Scientiﬁc). qRT–PCR was performed on a Chromo4
Real-Time PCR detection system (Bio-Rad), as follows:
95  for 2min followed by 40 cycles of 95  for 30s, 60 
for 30s and 72  for 10s. A concentration curve of the
trans-spliced product, puriﬁed using the QIAquick PCR
puriﬁcation kit (Qiagen), was determined using the
Opticon Monitor3 software supplied with the Opticon4
apparatus. This concentration curve was used to deter-
mine the amount of PCR product produced in each
sample. The reverse transcription could be performed
using random-primers or primer speciﬁc to luciferase
(216-Luc 66-68as). However, the random priming
enabled simultaneous detection of the controls and the
spliced product.
RESULTS
Constructing a pre-mRNA for in vitro trans-splicing
In vivo trans-splicing takes place on polycistronic
pre-mRNA. A scheme depicting such a pre-mRNA is
given in Figure 1A, highlighting the essential sequences
required for trans-splicing including the 30 AG splice
site, polypyrimidine tract (PPT), branch point and the
polyadenylation signal of the upstream gene.
Plasmid pNS-21 was used in this study; this vector was
previously used to study the optimal composition and
distance between the AG splice and the PPT for trans-
splicing (28). The sequences in the intergenic region of
the vector are partially synthetic and lack the
polyadenylation signal of an upstream gene. Because of
the previously shown linkage between trans-splicing and
polyadenylation (28,32–34), we replaced the intergenic
region with authentic sequences. The sequences between
the BglII site and the XbaI site were replaced by either the
Figure 1. (A) Schematic presentation of a trypanosome polycistronic pre-mRNA. The signiﬁcant sequence elements essential for trans-splicing are
indicated. (B) Pre-mRNA substrates used in this study. Schematic representation of the pre-mRNA substrates highlighting the signiﬁcant sequence
elements: polyadenylation site (polyA site), polypyrimidine tract (PPT) and AG splice site. The lengths of the PIR and TIR UTRs as well as the
Luciferase ORF are indicated. Underneath each pre-mRNA, the respective probe, in vitro trans-spliced product and endogenous mRNA are shown,
along with the expected size of the protected fragments after RNase protection. (C) RNase protection assay to monitor the expression of the TIR
and PIR constructs. (a) Thirty micrograms of total RNA was hybridized with labeled antisense probe, complementary to the trans-spliced product, as
described in ‘Materials and Methods’ section. Protected RNA products were separated on a 6% sequencing gel. M- DNA marker, labeled pBR322
DNA MspI digest. The size of the marker is indicated on the left. Lane contents are as follows: 1, RNA from parental strain; 2, RNA from
transgenic parasites expressing the pNS21-PIR construct; 3, RNA from transgenic parasites expressing the pNS21-TIR construct. The scheme on the
right hand side of the gel indicates the structure of the probe and the protected fragments. (b) Relative expression of the tubulin-luciferase or the
EP-luciferase to the endogenous tubulin and EP transcripts.
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(pNS21-TIR) or the 630bp EP-3-2 intergenic region
(pNS21-PIR) (Supplementary Figure S2). Transgenic par-
asites were obtained and the expression of the luciferase
gene was determined by northern analysis. The results
indicated that the presence of the authentic intergenic
regions of either tubulin or EP enhanced the expression
of the luciferase gene compared to the parental pNS21
(data not shown). Since these constructs diﬀer at the 50
ﬂanking sequences, especially in the sequences upstream
to the AG splice site, the diﬀerence in expression most
probably reﬂects diﬀerences in trans-splicing eﬃciency.
To establish an assay that would directly measure the
production of the trans-spliced product from pre-mRNA,
we prepared an antisense RNA probe (carrying a small
extension at the 50-end to distinguish the probe from the
protected fragments) using a cDNA clone derived from
the transgenic parasites as a template. The RNase protec-
tion assay was used to examine the production of the
trans-spliced products in parasites expressing either the
TIR or PIR constructs. Schematic presentation of TIR
and PIR constructs and the fragments that are generated
from the RNase protection are depicted in Figure 1B.
Three fragments were observed: (I) the residual undigested
probe; (II) the trans-spliced product; and (III) the
endogenous transcript. Based on the ratio between the
trans-spliced product (II) and the endogenous transcript
(III), it was evident that the PIR construct was more
highly expressed and trans-spliced compared to the TIR
transcript (Figure 1C-b compare lanes 2 to 3). As a control
for the speciﬁcity of the assay, RNA from the parental
strain was used, and the only protected fragment was of
the endogenous tubulin transcript (lane 1). These results
suggested that we established a chimeric construct that is
properly trans-spliced in vivo and can be used as a
substrate for establishing the in vitro trans-splicing
reaction.
In vitro reaction with the PIR and TIR pre-mRNA
Several parameters were considered when establishing the
in vitro reaction. Diﬀerent protocols were used to prepare
nuclear extracts (35,36) and a whole-cell extract (29). The
eﬃciency of SL RNA transcription was examined in the
extracts using an SL RNA gene plasmid harboring a 19-nt
insertion mutation, and primer extension using a primer
speciﬁc for the insertion (37). The results (data not shown)
indicated that in our hands the most active transcription
extract was the whole-cell extract prepared according to
Laufer et al. (29). Note, that sucrose was used both for
freezing the extract and in the reaction, rather than
glycerol or sorbitol, which are used to stabilize the mam-
malian and yeast extracts, respectively. This change stems
from the fact that the trypanosome extracts are highly
enriched in glycolytic enzymes that require ATP, and
hence, addition of glycerol depletes the ATP in the
extract. It was previously reported that when the counter
ion chloride is replaced by glutamate, the in vitro tran-
scription in the trypanosome extracts is more eﬃcient
(35). Potassium glutamate was therefore used in the
reaction. The ﬁrst step was to determine if a trans-
spliced product is generated in the reaction using T7
in vitro transcribed pre-TIR or pre-PIR mRNAs. The
source of SL RNA was the endogenous SL RNP present
in the extract. The reaction was terminated by extraction
of the RNA, and the RNA was subjected to RNase pro-
tection with the corresponding probes. The RNase protec-
tion was performed in parallel on RNA extracted from
transgenic parasites expressing the TIR and PIR con-
structs (Figure 2). Three fragments, whose identities are
illustrated schematically on the right side of the gel, were
Figure 2. In vitro trans-splicing of synthetic pre-mRNA using T. brucei whole-cell extract. (A) A total of 0.5mg pNS21-TIR pre-mRNA was
incubated in a 20ml reaction ( 300mg of extract), in transcription buﬀer, for 1h at 28 C, as described in ‘Materials and Methods’ section. RNA
was extracted and subjected to RNase protection assay with an antisense probe complementary to the tubulin-luciferase trans-spliced transcript as
described in ‘Materials and Methods’ section. Lane contents are as follows: 1, The PIR antisense probe; 2, RNase protection of RNA from
transgenic pNS21-PIR; 3, RNase protection of RNA from the in vitro reaction with pre-PIR mRNA. (B) The same as in (A) but using the
pNS21-TIR pre-mRNA. Lane contents are as follows: 1, The TIR antisense probe; 2, RNase protection of RNA from transgenic pNS21-TIR; 3,
RNase protection of RNA from the in vitro reaction with pre-TIR mRNA. In both panels, the RNA products were separated on a 6% denaturing
gel. M- DNA marker, labeled pBR322 DNA MspI digest. The size of the marker bands are indicated in nt. The identity of the diﬀerent fragments is
schematically illustrated.
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reaction: (i) residual undigested probe, which migrates
like the probe (Figure 2A and B, lane 1); (ii) the trans-
spliced product (Figure 2A and B, lane 3), seen as the
protected fragments present in the RNA from the
in vitro reactions. The protected fragments were identical
to the fragments detected when RNA from transgenic
parasites was used (compare lanes 2 to 3); and
(iii) pre-mRNA; the intensity of the protected fragment
indicates the extent of pre-mRNA that existed at the end
of the reaction (present only in lane 3). Although the same
amount (0.5mg) of both pre-TIR and pre-PIR were added
to the reaction, massive degradation of pre-PIR was
observed in the extract. The trans-spliced product
(lanes 3) was excised from the gel, ampliﬁed using the
SL forward primer and the luciferase reverse primer
(described above) and sequenced. The sequence was iden-
tical to the product observed in the transgenic lines, sug-
gesting that the reaction is faithful and generates a genuine
trans-spliced product. The eﬃciency of the reaction was
estimated by examining the fraction of pre-mRNA that
was converted to trans-spliced product. The results were
analyzed by densitometry and the intensity of the spliced
product was divided by the intensity of the pre-mRNA.
While this approach gives only a very rough estimation,
our results indicate that between 0.5% and 2% of the
pre-mRNA is trans-spliced. Note that the pre-mRNA is
present in vast excess (see below).
The trans-splicing reaction is heat sensitive and
requires ATP
To examine if the reaction shares known properties of
in vitro splicing reactions (22–24), two requirements
must be met. The reaction should be inactivated by heat
and should depend on the presence of ATP. The results in
Figure 3A demonstrate that heat inactivation (incubating
the extract for 30min at 55 C) abolished the production of
the trans-spliced product (compare lanes 2 to 3). The
position of the trans-spliced product was determined by
the migration of trans-spliced product generated from
RNA extracted from the transgenic line expressing the
TIR plasmid (lane 1). Next, the dependence of the
reaction on ATP was examined. If the ATP regenerating
system was omitted from the reaction, no trans-spliced
product was generated (Figure 3B, compare lanes 4 and
5). If the reaction lacked pre-mRNA, and instead the TIR
plasmid was added to the reaction under transcription
conditions, pre-mRNA was produced but no trans-
spliced product was detected, suggesting that the amount
of pre-mRNA produced in vitro did not enable the detec-
tion of the trans-spliced product (Figure 3B, lane 3). Next,
we examined the time dependence of the reaction; the
results demonstrate that the reaction was linear up to
60minutes (Figure 3C and D). No increase in the trans-
spliced product was observed thereafter, most probably
because of consumption of all the SL RNA present in
the extract. The degradation of the pre-mRNA most
probably takes place immediately after addition of the
pre-mRNA, since no change in the level of protected
pre-mRNA was observed at longer incubation times,
suggesting that the pre-mRNA is protected from further
degradation once it is assembled into splicing complexes
(Figure 3C; compare lanes 1–3).
Optimization of the reaction conditions
Salt concentration, the level of MgCl2, the concentration
of reactants and the identity of the acceptor and donor
RNAs can all dramatically change the yield of the trans-
splicing reaction. Thus, it was necessary to determine the
optimal concentration of each of these constituents within
the reaction. Previously, the type of counter ion used was
shown to aﬀect the in vitro transcription reaction.
Changing KCl to K-glutamate increases the eﬃciency of
SL RNA transcription (35). Thus, the in vitro reaction was
incubated in the presence of elevated salt concentration,
and the production of the trans-spliced product was mon-
itored. The results shown in Figure 4A indicate that
40mMK-glutamate was the optimal salt concentration.
As expected, at higher salt concentrations, above
60mM, the reaction was completely inhibited. Next, the
eﬀect of MgCl2 concentration was examined and the
results indicate that 3mM MgCl2 was optimal (results
not shown). The amount of pre-mRNA was also
examined, and the results (Figure 4B) indicate that a rel-
atively high concentration (0.5mg per reaction) was needed
to enable production of the trans-spliced product. These
results demonstrate that the RNase protection assay
reﬂects the increased amount of pre-mRNA present in
the reaction. Note that concentrations higher than 0.5mg
poison the reaction. The results in the right panel present
the quantiﬁcation data from three independent
experiments.
Addition of endogenous SL RNA but not in vitro
transcribed SL RNA enhances the reaction eﬃciency
The trans-splicing reaction depends on the supply of
endogenous SL RNA for the reaction to proceed.
However, SL RNA might be a limiting factor in the
extract. Exogenous SL RNA must ﬁrst assemble into its
cognate particle, the SL RNP, before it can participate in
the reaction. The assembly of SL RNA into its particle
was compared using in vitro transcribed SL RNA versus
the assembly of native SL RNA that was synthesized in
permeable cells. The results presented in Figure 5A-a,
lanes 1 and 2, suggest that 100% of the native SL RNA
prepared in permeable cells was incorporated into the SL
RNP particle, whereas <1% of the in vitro transcribed SL
RNA was assembled into the SL RNP (lanes 5 and 6).
SL RNP assembly with the radiolabeled SL RNA was
competed by the addition of cold-endogenous SL RNA
(compare lanes 2 to 3) but not by tRNA (compare lanes 2
and 4). The assembly of SL RNA into the SL RNP was
optimal when the reaction was performed with 4mM
MgCl2 and 30mMK-glutamate (Figure 5A-b), conditions
very similar to those used in the in vitro reaction
(Figure 4).
Next, we examined whether addition of native SL RNA
or in vitro transcribed SL RNA to the in vitro splicing
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trans-spliced product. Addition of increasing amounts of
endogenous SL RNA (up to 3ng), increased the eﬃciency
of the reaction, suggesting that the SL RNP is limiting in
the extracts (Figure 5B). In contrast, addition of
increasing amounts of synthetic SL RNA (up to 2mg)
had no eﬀect on the production of trans-spliced product
(Figure 5C-a); This result was expected based on the much
more eﬃcient assembly of endogenous SL RNA relative to
the synthetic molecule. Next, it was determined if in vitro
transcribed SL RNA containing an m
7G cap could be
used as a substrate for in vitro trans-splicing. Addition
of up to 2mg of synthetic m
7G capped SL RNA did not
increase the generation of the trans-spliced product
(Figure 5C-b). This synthetic SL RNA also failed to eﬃ-
ciently assemble into SL RNP (data not shown),
suggesting that the cap-4 modiﬁcation might be necessary
for SL RNP biogenesis. Therefore, increasing amounts of
synthetic cap-4 (38) were added to the reaction. Figure 5D
shows that adding cap-4 at concentrations up to 50mM
did not aﬀect the reaction. Thus suggesting that cap-4
needs to be attached to the SL RNA in order to
promote proper SL RNP assembly and that cap-4
provided in trans can not interfere with this process.
The absence of the +4 cap modiﬁcation does not aﬀect
in vitro trans-splicing
To examine the dependence of trans-splicing in vitro on
cap-4, we prepared an extract from SmD1-silenced cells.
In these silenced cells, trans-splicing is inhibited, and
SL RNA lacking modiﬁcation at the +4 position of
Figure 3. The trans-splicing reaction is heat-inactivated, requires ATP and is time-dependent. (A) Trans-splicing in heat-inactivated extracts. For heat
inactivation, the trans-splicing extract was incubated for 30min at 55 C. The trans-splicing product was compared to that produced in untreated
extract. Total RNA was prepared from the reaction and subjected to RNAse protection as described in ‘Materials and Methods’ section. Lane
contents are as follows: 1, RNase protection assay with RNA (30mg) from pNS21-TIR transgenic cells; 2, In vitro trans-splicing reaction using
untreated extract (control); 3, In vitro trans-splicing reaction using heated-inactivated extract. (B) Co-transcriptional trans-splicing and ATP require-
ment of the trans-splicing reaction. In vitro trans-splicing was performed in the presence of 0.8mg pNS-21-TIR plasmid DNA as described in the
‘Results’ section. For ATP depletion, the ATP regenerating system was omitted from the reaction. After incubation at 28 C for 1h, total RNA was
prepared and subjected to RNase protection as described in ‘Materials and Methods’ section. Lane contents are as follows: 1, Antisense probe
(500c.p.m.); 2, total RNA (30mg) from the transgenic pNS21-TIR cells; 3, RNA from extracts containing plasmid pNS21-TIR; 4, RNA from trans-
splicing reaction lacking the ATP regenerating system; 5, RNA from trans-splicing performed under optimal conditions (control). M- DNA marker,
labeled pBR322 DNA MspI digest. (C) Kinetics of the in vitro trans-splicing reaction. In vitro trans-splicing was conducted under standard conditions
but for diﬀerent durations (100,6 0 0 and 1200). RNA was subjected to RNase protection as described in ‘Materials and Methods’ section.
(D) Quantitation of the time-dependent splicing from three independent experiments.
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variable, and silencing is not very eﬃcient if cells are
silenced in large quantities. The silenced population also
contains cells that are unaﬀected, and thus Sm proteins are
nevertheless present to some extent in the extracts. When
extracts are made from such cells, the majority of SL
RNA however, is ‘defective’ SL RNA. First, we
examined if SL RNA synthesized from SmD1-silenced
cells can assemble eﬃciently into SL RNP particles. SL
RNA was prepared from SmD1-silenced permeable cells.
The SL RNA synthesized under these conditions lacks
the +4 cap-4 modiﬁcation and possesses a 5-nt 30 tail
(14). Defective SL RNA synthesized in permeable
SmD1-silenced cells was able to assemble properly into
SL RNP particles (Figure 6A compare lanes 2 and 4).
Next, we examined the capacity of extracts prepared
from SmD1-silenced cells to carry out the in vitro trans-
splicing reaction. Using these extracts, two distinct
protected fragments were observed compared to a single
protected fragment observed when wild-type splicing
extract was used (Fig. 6B, compare lanes 1 and 2). In
lane 2, the lower protected fragment represents splicing
from the residual wild-type SL RNA present in the
extract, and the upper fragment from splicing of defective
SL RNA. The diﬀerence in size may reﬂect the fact that
SL RNA lacking the cap-4 modiﬁcation protects the last
four hypermodiﬁed nucleotides. The results also suggest
that SL RNA lacking the cap-4 +4 nucleotide and har-
boring a 5-nt tail can serve as a bona-ﬁde trans-splicing
substrate.
Inactivation of U2 or U6 snRNA reduces the splicing
eﬃciency
It was previously demonstrated that trans-splicing is
inhibited in permeable trypanosome cells when either U2
or U6 snRNAs are inactivated by RNase H cleavage (39).
To examine if trans-splicing in vitro relies on the presence
of intact U2 and U6 snRNAs, extracts were incubated
with U2 and U6 antisense oligonucleotides and RNase
H. U3 cleavage was used as a control. The same
oligonucleotides, U2SSC and U6-15, were previously
used to inactivate these snRNAs in permeable cells (39).
Cleavage reduced the level of U2 and U6 snRNA by 50%
and 40%, respectively, as evident by primer extension
that was performed on RNA extracted from the
oligonucleotide-RNAse H treated extracts (Figure 7B
and C). Indeed, in extracts depleted of these snRNAs,
the production of the trans-spliced product was reduced
by 60% and 45%, in accordance with the reduction in
snRNAs (Figure 7A; lanes 4 and 5). These results
suggest that, as expected, the reaction depends on the
snRNAs that constitute the catalytic center of
pre-mRNA splicing (40). The cleavage of U3 did not
aﬀect the level of U2 (Figure 7B, lane 2) or U6 (Figure
Figure 4. Optimization of the in vitro trans-splicing reaction. (A) Eﬀect of potassium-glutamate concentration on the reaction. In vitro trans-splicing
reactions were carried out for 1h at 28 C in the presence of 20, 40, 60, 80 and 100mMK-glutamate (lanes 2–6). RNA was extracted and subjected to
RNase protection. (B) Eﬀect of increasing pre-mRNA concentration on the reaction. In vitro trans-splicing reactions were carried out in the presence
of 25, 50, 125, 250 and 500ng pNS21-TIR pre-mRNA (lanes 2–5). RNA was extracted and subjected to RNase protection. RNA samples from the
diﬀerent reactions were separated on a 6% sequencing gel. M- DNA marker, labeled pBR322 DNA MspI digest. P- Probe (500c.p.m.). The identity
of the fragments is presented schematically. The right panels show the quantitation of three independent experiments.
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lane 3).
Mutations in the 30 splice and polypyrimidine tract
compromise the production of the trans-spliced product
The AG splice site and the PPT are sequences essential for
trans-splicing (28,32,33). It was therefore essential to dem-
onstrate that the production of the trans-spliced product is
aﬀected if these sequences are mutated. To this end, muta-
tions were introduced to the AG splice site and the PPT,
as illustrated in Figure 8A. Mutations were constructed
and the mutated genes were cloned into the pNS21
vector. Transgenic parasites were obtained, and the pro-
duction of the trans-spliced protected fragment was
examined by RNase protection assay using RNA
isolated from the transgenic parasites. The results demon-
strate (Figure 8B) that the AG to AA mutation reduced
Figure 5. Assembly of authentic and synthetic SL RNA and their eﬀect on trans-splicing. (A)( a) Assembly of the SL RNP. Nuclear extract (50mg)
was mixed with 5 10
3c.p.m. of SL RNA synthesized in permeable cells or 2   10
5c.p.m. of in vitro transcribed SL RNA under splicing conditions.
The complexes were separated on 6% native acrylamide gel, as described (56). The position of the SL RNA and SL RNP are indicated. Lane
contents are as follows: 1, Free SL RNA transcribed in permeable cells; 2, reconstitution of the particle using SL RNA transcribed in permeable cells;
3, the same as in lane 2, but 2ng of gel-puriﬁed SL RNA was added to the reaction; 4, the same as in lane 2, but 300ng of tRNA was added to the
reaction; 5, SL RNA synthesized in vitro; 6, assembly in vitro transcribed SL RNA. (b). Assembly of SL RNP in the presence of elevated MgCl2 and
K-glutamate levels. Assembly was as described in section (a), but in the presence of elevated MgCl2 (2.5, 4, 6, 8, 12mM MgCl2) (lanes 2–6) and
K-glutamate (20, 30, 40, 75, 100mM) (lanes 7–11). The reactions were separated on a 6% native gel next to free RNA (lane 1). (B)( a) Addition of
endogenous transcribed SL RNA increase trans-splicing eﬃciency. SL RNA was extracted from a gel, and its level was quantiﬁed by primer
extension. The in vitro reaction was performed under standard conditions in the presence of elevated SL RNA (0, 1, 2, 3ng) (lanes 2–5). The in
vitro reaction was subjected to RNase protection assay. M-marker; labeled pBR322 DNA MspI digest P, antisense probe. (b) Quantitation of the
increase in trans-spliced product. The data are based on three independent experiments. (C)( a). Addition of in vitro transcribed SL RNA does not
increase trans-splicing eﬃciency. In vitro trans-splicing was performed under standard conditions in the presence of elevated levels of in vitro
transcribed SL RNA (0, 1, 2mg) (lanes 2–4). The in vitro reaction was subjected to RNase protection assay. M- marker; labeled pBR322 DNA
MspI digest P, antisense probe. (b) Addition of in vitro transcribed m
7G capped SL RNA does not increase trans-splicing eﬃciency. In vitro trans-
splicing was performed under standard conditions in the presence of elevated levels of in vitro transcribed m
7G capped SL RNA (0, 1, 2mg) (lanes 2–
4). The in vitro reaction was subjected to RNase protection assay. M- marker; labeled pBR322 DNA MspI digest C, total RNA (30mg) from the
transgenic pNS21-TIR cells. (c) Quantitation of the increase in trans-spliced products upon addition of in vitro transcribed SL RNA. The data are
based on three independent experiments. Solid line, addition of uncapped in vitro transcribed SL RNA; dotted line, addition of m
7G capped in vitro
transcribed SL RNA. (D) The eﬀect of cap-4 on trans-splicing. The in vitro trans-splicing reaction was carried out in the presence of increasing
amount of synthetic cap-4 (0, 5, 50, 500, 5000 nM) (lanes 2–6). M-DNA marker, labeled pBR322 DNA MspI digest P-Probe (500c.p.m.). The
identity of the fragments is presented schematically.
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(compare lanes 1 and 2), whereas the PPT mutation
reduced the production of the trans-spliced product by
 70% compared to the wild-type transcript (compare
lanes 1 and 3). cDNA was prepared from the transgenic
parasites and ampliﬁed with the SL forward primer and
antisense luciferase primer. Although the RNase protec-
tion assay showed complete inhibition of the production
of trans-spliced product using the RNase protection assay
(Figure 8B), a PCR product was nevertheless obtained
after PCR ampliﬁcation. Sequence analysis indicated
that SL was added exclusively 9-nt downstream to the
authentic AG splice site, suggesting that, in the absence
of a bonaﬁde site, the splicing system ‘scans’ for an alter-
native AG splice site.
To investigate whether the splicing signal mutants are
trans-spliced in vitro similarly to their splicing in vivo,
pre-mRNAs were prepared from the mutants and the pro-
duction of the trans-spliced product was examined. The
results (Figure 8C) suggest that both mutations aﬀected
the ability to form the spliced product. The reduction in
the formation of the trans-spliced product for the AA and
PPT mutants was 60% and 70%, respectively
(Figure 8C-b). Interestingly, the PPT mutation aﬀected
the in vitro reaction more strongly than its eﬀect in vivo.
The AA mutation, however, had a less severe eﬀect in vitro
compared to in vivo (compare Figure 8C-a, lanes 3 and 5
to Figure 8B-a, lanes 2 and 3).
Generating a TIR mutation downstream to the AG splice
site to produce a model substrate for RT–PCR or
real-time PCR assays
The RNase protection assay used to monitor the produc-
tion of the trans-spliced product is a very laborious and
time-consuming assay. However, it allows examination of
the trans-spliced product without any ampliﬁcation and
is therefore less prone to artifacts compared to assays
that involve ampliﬁcation. Nevertheless, the technical
diﬃculties in the RNase protection assay led us to
develop an alternative RT–PCR assay that involves an
ampliﬁcation step. Performing RT–PCR on an in vitro
reaction, using the pre-TIR as a substrate and the same
oligonucleotides that were used to produce the cDNA in
the transgenic parasites, produced a trans-spliced product
whose production was insensitive to ATP depletion or to
heat inactivation, suggesting that ampliﬁcation can take
place that is not dependent on trans-splicing. We therefore
generated a 20-nt substitution mutation 2-nt downstream
of the AG splice site (Figure 9A). The mutant was
cloned into pNS-21, and cell lines were generated
(pNS21-TIRsub). RNA was prepared from the cell line
and used to amplify the cDNA using pairs of forward
(SL) and antisense primers speciﬁc to the mutation
(Figure 9C). No such product could be ampliﬁed using
cDNA from cells expressing pNS21-TIR. The PCR
product was sequenced and the results indicated that SL
was added to the authentic site. Next, an antisense RNA
probe was made from this clone and used in the RNase
protection assay. The results in Figure 9D show that the
protected fragment appeared only in RNA extracted from
the mutant but not from the parental strain (compare
lanes 1 and 2). Pre-mRNA was produced from
pNS21-TIRsub, and the production of the in vitro trans-
spliced product was examined by RNase protection assay.
Production of the trans-spliced product was observed,
and was dependent on ATP and inactivated by heat
(Figure 10B, compare lanes 1 to 3). Next, we examined
the same RNA in the RT–PCR assay. cDNA was
Figure 6. Trans-splicing using extracts from SmD1-silenced cells.
(A) SL RNA produced in SmD1-silenced cells can assemble into
SL RNP. Nuclear extract (50mg) was mixed with 5 10
3c.p.m. of
SL RNA synthesized in permeable parental cells or SmD1-silenced per-
meable cells. The complexes were separated on a 6% native acrylamide
gel. Lane contents are as follows: 1, SL RNA synthesized in parental
permeable cells; 2, reconstitution of SL RNP using parental cell extract;
3, free SL RNA synthesized in SmD1-silenced cells; 4, reconstitution of
SL RNP in extracts prepared from SmD1-silenced cells. (B) In vitro
trans-splicing reactions. The in vitro reaction was conducted with
parental cell extracts or extracts prepared from the SmD1-silenced
cells. SmD1 extracts were prepared from 5 10
9 cells 3 days after tet-
racycline addition as described (14). The RNA puriﬁed from the reac-
tions was subjected to RNase protection. M- DNA marker, labeled
pBR322 DNA MspI digest P- Probe (500 c.p.m.). Lane contents are
as follows: 1, RNA from in vitro trans-splicing using parental strain
extract; 2, in vitro trans-splicing using extracts from SmD1-silenced
cells; 3, in vitro trans-splicing extract without pre-mRNA; 4, RNA
from transgenic parasites expressing pNS21-TIR; 5, RNA from
parental strain. RNA from the protection assays was separated on
6% acrylamide denaturing gels.
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cDNA was ampliﬁed with three diﬀerent pairs of
oligonucleotides, a pair to amplify the pre-mRNA, the
endogenous tubulin mRNA, and the trans-spliced
product. The trans-spliced product was ampliﬁed with
an antisense oligonucleotide complementary to the
mutation and a forward SL oligonucleotide. The results
indicate that identical amounts of pre-mRNA and extract
(based on a tubulin control) were present in each reaction
(Figure 10A, lanes 2 to 4), but the level of the trans-spliced
product was sensitive to conditions that aﬀected splicing.
Thus, the RT–PCR results are in agreement with the
RNase protection assay, and show 85% and 96% reduc-
tion in the formation of the trans-spliced product
under ATP depletion or heat-inactivation, respectively
(Figure 10).
Real-time PCR
In order to quantify the exact amount of PCR product
that is ampliﬁed from the in vitro trans-splicing reactions,
and to show that the RT–PCR performed above was done
while the reaction was in exponential phase, qRT–PCR
was performed. A melting curve was performed to show
that only a single trans-spliced product was ampliﬁed
during the qRT–PCR, and the melting curve was identical
for the fragment formed using the cDNA from the
transgenic parasite and from the in vitro reaction (results
not shown). Finally, a PCR product of known quantity
was used to establish a concentration curve. This concen-
tration curve was then used to determine the amount of
PCR product ampliﬁed from an in vitro trans-splicing
reaction. As can be seen in Figure 10C, a standard in
vitro trans-splicing reaction, in which 4 pmol of
pre-mRNA was added yielded 50 fmol of PCR product.
This is comparable to the amount of PCR product
ampliﬁed from 10mg of total RNA from transgenic para-
sites expressing pNS21-TIRsub. Performing qRT–PCR on
reactions in the absence of ATP or after heat inactivation
yielded  1 fmol and 0 fmol, respectively. The reduction in
PCR ampliﬁcation in the absence of ATP or upon heat
inactivation was similar to the reduction as determined by
RT–PCR and RNase protection. Thus, these experiments
establish three diﬀerent assays that faithfully monitor the
production of trans-spliced product generated in vitro
from synthetic pre-mRNA and endogenous SL RNA
and demonstrate some of the requirements for these
assays.
DISCUSSION
In this study, we describe for the ﬁrst time a system that is
able to faithfully monitor the formation of a chimeric
trans-spliced RNA product in vitro using a T. brucei
soluble cell extract and synthetic in vitro transcribed
pre-mRNA. The ability to establish such an in vitro
system stems from the reaction conditions and the sensi-
tive assays used in this study. The study demonstrates that
SL RNP is a limiting factor in the reaction, and only
endogenous SL RNA but not m
7G capped synthetic SL
RNA can be utilized. Interestingly, SL RNA lacking the
+4 cap modiﬁcation and possessing a 5-nt longer tail can
be utilized in vitro. The assembly of synthetic and
Figure 7. RNaseH digestion of U2 or U6 snRNAs inhibits in vitro trans-splicing. (A)( a) Whole-cell extract was incubated for 1h on ice with
oligonucleotides complementary to U3, U2 or U6 snRNAs, in the presence of 1U RNase H, as described in ‘Materials and Methods’ section. The
RNA from the diﬀerent reactions was analyzed by an RNase protection assay. RNA was separated on a 6% sequencing gel. Lane contents are as
follows: 1, Probe (500c.p.m.); 2, RNA from in vitro trans-splicing extract (control); 3, extract was subjected to RNase H cleavage with U3-speciﬁc
oligonucleotide; 4, extract was subjected to RNase H cleavage with U2-speciﬁc oligonucleotide; 5, extract was subjected to RNase H cleavage with
U6-speciﬁc oligonucleotide. M-DNA marker, labeled pBR322 DNA MspI digest. (b) Quantitation of the eﬀect on the production of the trans-spliced
product; data represent three independent experiments. (B) Primer extension to determine the amount of U2 snRNA after RNase H treatment.
Primer extension was performed on RNase H-oligonucleotide cleaved extracts using U2 speciﬁc primer (listed in S-1). The identity of the antisense
oligonucleotides used for cleavage is indicated. (C) Primer extension to determine the amount of U6 snRNA after RNase H treatment. Primer
extension was performed on RNase H-oligonucleotide cleaved extracts using U6 speciﬁc primer (listed in S-1). The identity of the antisense
oligonucleotides used for cleavage is indicated.
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cells suggests that the cap-4 modiﬁcations but not the
cap-4 +4 modiﬁcation are essential for SL RNP
assembly. The performance of the in vitro trans-splicing
reaction meets the requirements observed for other
splicing systems, speciﬁcally the dependence on ATP,
and on U2 and U6 snRNAs. Mutations in strategic posi-
tions such as the polypyrimidine tract and the AG splice
site compromised the reaction in vivo and in vitro.
The most essential factors for establishing the
in vitro system
The failure to date to establish an in vitro system in
trypanosomes lies in the use of radiolabeled pre-mRNA
substrates that were extensively degraded, and the deﬁ-
ciency in essential factor(s) in the extract. Massive
degradation of pre-mRNA was also observed in our
study. This degradation could not be eliminated even if
the mRNA was capped at the 50-end or at the 30-end with
pCp (our unpublished data). Our success in detecting the
trans-spliced product in this study lies in three parameters:
(i) the extract used is crude but contains all the factors
necessary for the reaction. It is prepared very rapidly to
eliminate the potential inactivation of essential factors.
However, because the extract is not puriﬁed, it contains
enzymes that may inactivate essential factors, thus
reducing the reaction eﬃciency. (ii) A large amount of
pre-mRNA is added to the reaction, leaving suﬃcient
amounts of substrate (after its immediate degradation)
to assemble into an active complex. The amount of
pre-mRNA (4 pmol) is 50-fold higher than the amount
of SL RNA in the extract ( 80 fmol). Indeed, we demon-
strate that increasing the amount of pre-mRNA increases
Figure 8. Trans-splicing eﬃciency is reduced in AG and PPT mutants. (A) Schematic representation of the mutations introduced in the AG 30 splice
site (30ss) and polypyrimidine tract (PPT) of b-tubulin upstream intergenic sequence. Generation of the mutants and preparation of the corresponding
cell lines were performed as described in ‘Materials and Methods’ section. (B)( a) In vivo trans-splicing in transgenic parasites expressing the
pNS21-TIR mutants. The level of the expressed trans-spliced product was measured by RNase protection using an antisense probe. RNA from
the RNase protection assays was separated on a 6% acrylamide/denaturing gel. Lane contents are as follows: 1, RNA from cells expressing the
wild-type transcript (pNS21-TIR); 2, RNA from cell lines expressing pNS21-TIRAAm; 3, RNA from cell lines expressing pNS21-TIRPPTm.
(b) Reduction in expression of the trans-spliced product relative to the wild-type transcript. The data are derived from three independent experiments.
(C)( a) In vitro trans-splicing of the AG and PPT mutants. Pre-mRNA was prepared from the mutants and the trans-splicing in vitro was compared
to that of wild-type transcripts. RNA from the in vitro reaction was subjected to RNase protection and the products separated on 6% denaturing
acrylamide gels. The identity of the RNA used in the reaction is indicated. M- DNA marker, labeled pBR322 DNA MspI digest. The identity of the
protected fragments is indicated. (b) Quantitation of the reduction in splicing. The results are derived from three independent experiments.
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this study. This is the most critical parameter that made it
possible to detect the trans-spliced product. Three diﬀer-
ent assays were used. In all the assays, only the
end-product but none of the intermediates are monitored.
The reaction eﬃciency, roughly calculated by the RNase
protection assay, is  1–2% of the input pre-mRNA
utilizing almost 50% of the SL RNA present in the
extract. Thus, the limiting factor in this system is the
SL RNA.
Although the traditional assays to monitor splicing so
far are based on the use of radiolabeled substrate, the
real-time PCR assay represents a much desired substitute.
It avoids the use of radiolabeled materials; it is quantita-
tive, and is able to quantitatively detect the amount of
trans-spliced product even at levels less than a few
femtomoles. In addition, the assay is convenient relative
to the RNase protection assay. Note that in all assays used
in this study, the in vitro trans-spliced product was
compared to the genuine trans-spliced product produced
in vivo in transgenic parasites.
An additional parameter that was essential for estab-
lishing the in vitro system was the choice of pre-mRNA
substrate. Our results indicate that the TIR pre-mRNA
was a better substrate than the PIR pre-mRNA. The
poor performance of the PIR substrate in vitro might
stem from its size. The larger substrate appeared more
vulnerable to degradation. In other splicing systems, it
was demonstrated that shortening both the exons and
the introns resulted in a substrate that is spliced more
eﬃciently (26). In addition, microarray data of the
transcriptome of cells silenced for splicing factors
suggest that EP splicing requires a high level of SR
proteins (Gupta and S.M., unpublished data). These
factors, in the proper phosphorylation form, might be
limited in the extracts used in this study. The choice of
the b-tubulin gene over a-tubulin was based on the ﬁnding
that eﬃcient a-tubulin splicing in vivo requires exonic
sequences present in the UTR. Such splicing might
require additional factor(s) to enhance the protein
binding to suboptimal sequences present in the vicinity
of the AG splice site of the a-tubulin transcript (33).
The eﬀect of pre-mRNA mutations on trans-splicing
in vivo and in vitro
One of the interesting results of this study is the diﬀeren-
tial splicing of the AG and PPT mutants in vivo and
in vitro. The mutation of AG to AA almost completely
abolished the production of the trans-spliced product in
vivo (Figure 8B). However, in vitro, only a 60% reduction
Figure 9. In vivo trans-splicing of the pNS21-TIRsub mutation by RT–PCR and RNase protection assay. (A) Schematic presentation of the sub-
stitution mutant. The PPT sequence and AG splice site are indicated, the sequence changes to create the mutation are marked. (B) The structure of
the trans-spliced product. The distance between the strategic domains is given in nt. The structure and size of the RT–PCR product is shown.
(C) RT–PCR assay to detect the trans-spliced product carrying the substitution mutation. cDNA was prepared from total RNA (10mg) of parental
and the pNS21-TIRsub expressing cell line, using random primers as described in ‘Materials and Methods’ section. The cDNA was ampliﬁed with
the SL forward primer and reverse primer speciﬁc for the mutation (see S-1). Lane contents are as follows: 1, PCR product of RNA prepared from
the cell line carrying pNS21-TIRsub; 2, cDNA prepared from parental strain; 3, cDNA was prepared from cells expressing pNS21-TIRsub. The PCR
product was separated next to size markers on a 10% acrylamide gel, and the gel was stained with ethidium bromide. (D) RNase protection assay to
detect the expression of pNS21-TIRsub. RNA was prepared from parental strain and from cells expressing the pNS21-TIRsub construct. After
RNase protection with antisense RNA probe complementary to the mutated RNA, the RNA was separated on a 6% denaturing acrylamide gel. The
identity of the fragments is indicated. M, marker, labeled pBR322 DNA MspI digest. Lane contents are as follows: 1, RNA from the cell line
expressing pNS21-TIRsub; 2, RNA from parental strain.
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from the transgenic parasites revealed the production of
a trans-spliced product where an alternative AG located
6-nt downstream to the authentic site was utilized. Using
this cDNA in an RNase protection assay showed that
alternative selection of this splice site took place when
either wild-type transcript or the mutant AG to AA
were used in vitro (our unpublished data), suggesting
that in vitro, as opposed to in vivo, an alternative AG
splice site can be chosen.
The diﬀerence between the in vivo and the in vitro utili-
zation of the AG to AA mutant and the choice of an
alternative AG splice site may be explained by the
shortage in the extract of a factor that functions in
selecting the optimal AG splice site. One such candidate
is the U2AF65 homologue (20). Our recent study indicates
that this large protein (90kDa) is subjected to proteolysis
in the extract. In addition, the active protein is
phosphorylated, and the presence of phosphatases in the
extract may render this factor inactive.
The PPT mutation, like the splice site mutation, had a
diﬀerent eﬀect in the in vitro reaction. This mutation
aﬀected the in vitro reaction as strongly as the AG to
AA mutation. In mammals, mutation or deletion of the
AG splice site completely blocks ligation (step2), while the
ﬁrst step proceeds, albeit at reduced eﬃciency. In contrast,
mutation of the PPT drastically reduces the eﬃciency of
the ﬁrst step; thus, the PPT sequence seems to be more
important in splicing than the AG dinucleotide (41). In
yeast, the 30 splice site mutations activate a cryptic AG
splice site even if this is not preceded by a PPT (42),
while in mammals, the cryptic 30 splice site is always
preceded by a PPT (43). These results suggest that PPT
recognition is more essential in mammalian than in yeast
splicing. The PPT seems to also be very important for
trans-splicing, especially in vitro. The trypanosome PPT
was shown to be essential for trans-splicing and
polyadenylation of the upstream gene (44–46).
Mutations introduced in the PPT of trypanosome
pre-mRNA suggest that although the size of the PPT
does not have a large eﬀect on the trans-splicing eﬃciency,
its composition does. Replacing uridines with two or three
consecutive purines severely compromises in vivo trans-
splicing (28). Indeed, the mutation we introduced not
only reduced the level of U’s within the tract but
inserted consecutive purines into the PPT site (Figure 8A).
Endogenous SL RNA but not synthetic SL RNA can
enhance the in vitro reaction
In nematodes, in vitro transcribed radiolabeled SL RNA is
properly capped and eﬃciently utilized in the in vitro
trans-splicing reaction (25). This is not the case with the
trypanosome SL RNA. The special cap-4 is added to the
SL RNA co-transcriptionally (47), and capping requires
that the nascent SL RNA adopt a special conformation
dictated by its interaction with SLA1 (11). Sm assembly is
coupled with the cap-4 +4 modiﬁcation (14); therefore,
the in vitro transcribed SL RNA can not assemble eﬃ-
ciently with the Sm core proteins, and hence, the SL
RNA is subject to major degradation. Indeed, in the
reconstitution experiments presented in Figure 5A, we
could not detect unassembled SL RNA; such RNA is
most probably rapidly degraded in the extract. The
capping of SL RNA by m
7G neither improved its stability
(our unpublished data), nor its ability to be utilized in the
trans-splicing reaction (Figure 5C-b). The in vitro
Figure 10. Detection of the trans-spliced product by RT-PCR and
real-time PCR. (A) RT–PCR assay of the in vitro trans-splicing
reaction. RNA was prepared from transgenic cells expressing
pNS21-TIRsub and from in vitro trans-splicing assays using
pre-mRNA of TIR-sub. cDNA was prepared from the diﬀerent
samples and was subjected to ampliﬁcation with the diﬀerent probes
(pre-mRNA, tubulin and the primers speciﬁc for pNS21-TIRsub), as
described in ‘Materials and Methods’ section. The primers are listed in
S-1. The PCR product was separated on a 10% acrylamide gel and
stained with ethidium bromide. The in vitro reaction was performed in
the absence of ATP regenerating system or using heat-inactivated
extract, prepared as described in Figure 3. Lane contents are as
follows: 1, cDNA from cell line expressing pNS21-TIRsub; 2, cDNA
prepared from in vitro reaction performed under standard conditions; 3,
cDNA prepared from in vitro trans-splicing performed in the absence of
ATP regenerating system; 4, cDNA prepared from in vitro trans-
splicing using a heat-inactivated extract. (B) RNase protection assay.
RNA prepared from the in vitro reactions performed in Panel A was
subjected to RNase protection assay. The RNA was separated on a 6%
denaturing gel. Lane contents are as follows: 1, RNA from in vitro
trans-splicing using pre-TIRsub; 2, the same as in lane 1 but the in
vitro reaction lacked ATP regenerating system; 3, the same as in lane
1 but a heat-inactivated extract was used. The identity of the fragments
is indicated. (C) Quantitation of the real-time PCR reactions. Real
time-PCR was performed as described in ‘Materials and Methods’
section. The concentration curve was used to determine the total
amount of PCR ampliﬁed in each reaction. The results shown are the
average of three independent experiments. The designation of the dif-
ferent columns are: in vivo, the amount of PCR product (fmol) from
10mg total RNA extracted from the transgenic cell line; IVTS, amount
of PCR product (fmol) produced from a standard in vitro trans-splicing
reaction; –ATP, amount of PCR product (fmol) produced from an
in vitro trans-splicing reaction in the absence of the ATP regeneration
system; heat inactivation, amount of PCR product (fmol) produced
from one in vitro trans-splicing reaction using heat-inactivated extract.
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cognate particle (results not shown) and therefore can not
associate with the trans-spliceosome. In contrast, SL RNA
derived from SmD1-silenced cells that lack the +4 cap-4
modiﬁcation can properly assemble and be utilized in the
reaction (Figure 6B). Although the SmD1 SL RNA is
defective compared to the wild-type RNA, it contains all
the cap modiﬁcations with the exception of cap +4. This
may suggest that these modiﬁcations are crucial for SL
RNP assembly. Indeed, our results are in agreement
with the in vivo data demonstrating that an SL RNA
mutant in the cap-4 +4 nucleotide has only a minor
eﬀect on its utilization compared to mutations in the +1
and +2 cap nucleotides, which severely aﬀect trans-
splicing in vivo (9).
In mammalian cells, it was demonstrated that splicing is
enhanced by using capped pre-mRNA (48). In yeast,
however, addition of cap analogues does not aﬀect the
reaction (22). In trypanosomes, the cap-4 may have addi-
tional biological functions during SL RNP assembly,
other than just protecting the SL RNA from degradation.
The main function of cap-4 might not be in the splicing
reaction itself, but rather, in the assembly of functional SL
RNP. The cap modiﬁcation may serve as a landmark con-
trolling the ﬁdelity of SL RNA biogenesis; thus, only SL
RNA containing the majority of modiﬁcations can
properly assemble in vitro. Indeed, it was shown that
eﬀector proteins distinguish the fully methylated form of
the cap-4 from the incomplete cap structure. For instance,
the T. brucei nuclear cap-binding complex CBP20 binds
with higher aﬃnity to the mature cap-4 compared to
uncapped SL RNA (49). In Leishmania, homologues
of the cap-dependent translation initiation factor eIF4E
distinguish between diﬀerent SL RNA caps (50).
Interestingly, although cells can resist the loss of either
modiﬁcation at the cap-2 (51) or at positions 3 and 4
(51,52), it is not possible to derive viable cells with
complete loss of cap ribose methylation (53). Indeed,
in vitro transcribed SL RNA lacking all the
trypanosome-speciﬁc modiﬁcations can not assemble
into SL RNP nor participate in the trans-splicing
reaction in vitro. These modiﬁcations are therefore also
essential for trans-splicing.
One of future challenges will be to synthesize in vitro SL
RNA that can be utilized in the in vitro trans-splicing
reaction. It will be interesting to use SL RNA from cells
with knock-out of TbMTr1, TbMTr2, TbMTr3, or even a
TbMTr-2 and 3 double knock-out, to examine the ability
of undermethylated SL RNA to serve as a substrate in the
in vitro trans-splicing reaction. Once the modiﬁcations that
are most relevant for trans-splicing are identiﬁed, it may be
possible to synthesize in vitro the properly capped SL RNA
using the relevant recombinant methylating enzyme(s).
What is the signiﬁcance of an in vitro trans-splicing
system and how can the system be improved
In this study, we utilized the in vitro system to begin to
assess the role of cap modiﬁcation on the trans-splicing
reaction, and this can be further extended as outlined
above. However, there are still many additional open
questions related to our understanding of the mechanism
and the machinery of trypanosome trans-splicing. One
major question is identifying the protein factor(s) that
mediate the interactions between the SL RNP and the
pre-mRNA machinery. In addition, relatively little is
known about what protein factors and sequences are
essential for determining the trans-splicing eﬃciency and
the selection of the proper 30 AG splice site. Transgenic
parasites expressing reporter genes fused to upstream reg-
ulatory sequences were used to identify structural con-
straints within the 30 AG splice site, and the PPT was
shown to be highly essential for trans-splicing and its
linkage to polyadenylation (28,32–34). However, such
results may be inﬂuenced by mRNA stability, and the
translatability of the reporter gene. An in vitro system
will therefore help to determine the exact role of sequences
and factors in trans-splicing. Recently, we described two
polypyrimidine tract binding proteins in trypanosomes
that aﬀect both trans-splicing and mRNA stability (54).
However, in our studies, it was very diﬃcult to dissect the
contribution of these RNA binding proteins to trans-
splicing as compared to mRNA stability. The in vitro
system should assist in deﬁning the factors that are essen-
tial for trans-splicing of C rich polypyrimidine tract
pre-mRNAs that bind PTB. Thus, in vitro trans-splicing
could be used to study which factors and sequences are
required for diﬀerential trans-splicing, for example of the
three phosphoglyceratekinase genes present in the same
polycistronic unit in T. brucei (55). However, the immedi-
ate next goal is to identify factor(s) that might be missing
or inactivated in the extracts, resulting in their reduced
eﬃciency, especially for splicing genes that require addi-
tional factors. This can be achieved by either ‘spiking’ the
reaction with fractionated extracts, or adding factors such
as the U2AF65 homologue as recombinant proteins.
This study is only the ﬁrst step towards developing a
robust cell-free system that, together with data from
in vivo studies, should help to reveal the mechanism con-
trolling the eﬃciency and ﬁdelity of trypanosome trans-
splicing. Trans-splicing is one of the most essential mRNA
processing mechanisms in trypanosomes. This is the main
biochemical process that diﬀerentiates the host from the
parasite and therefore a better understanding of the mech-
anism may also identify novel targets for therapy.
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